Extended Data Fig. 1: Sonelokimab is a novel nanobody that binds to both IL-17A and IL-17F with a similarly high affinity and is designed to target difficult-to-reach sites of inflammation.
IL-17, interleukin-17; mAb, monoclonal antibody.
Extended Data Fig. 1: Sonelokimab is a novel nanobody that binds to both IL-17A and IL-17F with a similarly high affinity and is designed to target difficult-to-reach sites of inflammation. | Nature Medicine
